- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02996630
Assessing Neurodevelopment in Congenital Heart Disease. (NEUROHEART)
Abnormal Neurodevelopment Detection in Congenital Heart Disease: Predictive Methods Based on Prenatal and Postnatal Factors.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The main objectives of this study are: 1. to describe the neurodevelopmental outcome of patients with CHD at 24 months of age; 2. identify the subgroup with poorer outcome; and 3. evaluate the utility of fetal and postnatal diagnostic techniques for early detection of patients at risk for altered neurological outcomes.
Seven Spanish referral centers for CHD included in the research network on maternal and child health currently participating in this prospective multicentric case-control coordinated study. Fetuses with CHD (transposition of great arteries, tetralogy of Fallot, hypoplastic left heart syndrome and septal defects) will be studied from 24 weeks of gestation to 2 years of age. Diagnostic tests will be repeated throughout the study in all patients, from the fetal period to 24 months of age, and will include: fetal cerebral hemodynamic Doppler assessment, functional echocardiography, brain MRI, regional cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers analysis. Neurodevelopmental assessment will be made at 12 months of age using the ages and stages questionnaire (ASQ) and at 24 months of age with the Bayley-III test. From this data, statistical analysis will select the most useful as predictors of damage; to be then combined and create algorithms for predicting brain damage and poor neurodevelopment. Once description has been made, we will proceed to identify amongst our results, children with the poorest neurological outcome and remark possible common prenatal and early life markers in them as well as the CHD severity they present.
While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. Evidence available does not allow clinicians to assess on neurological prognosis although has opened up the possibility of finding prenatal markers of brain damage. Even though, no prospective studies have been performed until now. We present a multicentric prospective study able to recruit enough fetal CHD affected pregnancies to obtain neurological prognostic tools.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Irene Ribera, MD
- Telefonnummer: 3086 934893000
- E-post: irene.ribera@vhir.org
Studera Kontakt Backup
- Namn: Aina Ruiz, MD
- Telefonnummer: 3086 934893000
- E-post: aruizrom@gmail.com
Studieorter
-
-
-
Barcelona, Spanien, 08035
- Rekrytering
- Hospital Universitari Vall d'Hebron
-
Kontakt:
- Irene Ribera, Dr
- Telefonnummer: 3086 934893000
- E-post: irene.ribera@vhir.org
-
Kontakt:
- Elisa Llurba, Dr
- Telefonnummer: 3086 934893000
- E-post: irene.ribera@vhir.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Single pregnancies
- Major Congenital Heart Disease
- Informed Consent Signed
Exclusion Criteria:
- Major extra-cardiac malformations
- Parental Refusal to participate
- Maternal Chronic Disease
- Multiple Pregnancies
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Healthy fetuses
Pregnant patients carrying a healthy fetus.
Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
|
Fetal Ultrasound exploration
Fetal MRI for brain study
Neurodevelopment paediatric assessment test performed at 2 years of age.
Cord blood samples will be taken after birth in both groups.
|
Övrig: Congenital Hearth Disease
Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
|
Fetal Ultrasound exploration
Fetal MRI for brain study
Neurodevelopment paediatric assessment test performed at 2 years of age.
Cord blood samples will be taken after birth in both groups.
Congenital Heart Disease repair
EEG and continuous brain oximetry before surgery.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Bailey-III test punctuation
Tidsram: 45 minutes
|
Results in pediatric Bailey-III test scale
|
45 minutes
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Biparietal diameter (mm)
Tidsram: one day
|
Biparietal diameter (mm) measured with MRI
|
one day
|
Lateral sulcus depth
Tidsram: one day
|
Lateral sulcus depth (mm) measured with MRI
|
one day
|
Cerebral insula
Tidsram: one day
|
Insula (mm) measured with MRI
|
one day
|
Brain biometries
Tidsram: one day
|
Calcarine sulcus depth (mm)
|
one day
|
Cerebral cingulata sulcus
Tidsram: one day
|
Cingulata sulcus depth (mm) measured with MRI
|
one day
|
Corpus callosum
Tidsram: one day
|
Corpus callosum (mm) measured with MRI
|
one day
|
Cerebellum
Tidsram: one day
|
Cerebellum vermis (mm) measured with MRI
|
one day
|
Umbilical doppler
Tidsram: one day
|
Umbilical artery pulsatility index
|
one day
|
Middle cerebral artery doppler
Tidsram: one day
|
Middle cerebral artery pulsatility index
|
one day
|
Angiogenic PLGF (placental growth factor)
Tidsram: Two days
|
Placental growth factor in maternal serum
|
Two days
|
Angiogenic s-FLt (soluble fms-like tyrosine kinase)
Tidsram: Two days
|
Soluble fms-like tyrosine kinase factor in maternal serum
|
Two days
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studierektor: Elisa Llurba, MD, PhD, Hospital Universitari Vall d'Hebron
Publikationer och användbara länkar
Allmänna publikationer
- Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002 Jun 19;39(12):1890-900. doi: 10.1016/s0735-1097(02)01886-7.
- Bellinger DC, Jonas RA, Rappaport LA, Wypij D, Wernovsky G, Kuban KC, Barnes PD, Holmes GL, Hickey PR, Strand RD, et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med. 1995 Mar 2;332(9):549-55. doi: 10.1056/NEJM199503023320901.
- Limperopoulos C, Majnemer A, Shevell MI, Rosenblatt B, Rohlicek C, Tchervenkov C. Neurodevelopmental status of newborns and infants with congenital heart defects before and after open heart surgery. J Pediatr. 2000 Nov;137(5):638-45. doi: 10.1067/mpd.2000.109152.
- Masoller N, Martinez JM, Gomez O, Bennasar M, Crispi F, Sanz-Cortes M, Egana-Ugrinovic G, Bartrons J, Puerto B, Gratacos E. Evidence of second-trimester changes in head biometry and brain perfusion in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2014 Aug;44(2):182-7. doi: 10.1002/uog.13373. Epub 2014 Jul 8.
- Ruiz A, Cruz-Lemini M, Masoller N, Sanz-Cortes M, Ferrer Q, Ribera I, Martinez JM, Crispi F, Arevalo S, Gomez O, Perez-Hoyos S, Carreras E, Gratacos E, Llurba E. Longitudinal changes in fetal biometry and cerebroplacental hemodynamics in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2017 Mar;49(3):379-386. doi: 10.1002/uog.15970.
- Ribera I, Ruiz A, Sanchez O, Eixarch E, Antolin E, Gomez-Montes E, Perez-Cruz M, Cruz-Lemini M, Sanz-Cortes M, Arevalo S, Ferrer Q, Vazquez E, Vega L, Dolader P, Montoliu A, Boix H, Simoes RV, Masoller N, Sanchez-de-Toledo J, Comas M, Bartha JM, Galindo A, Martinez JM, Gomez-Roig L, Crispi F, Gomez O, Carreras E, Cabero L, Gratacos E, Llurba E. Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART): study protocol. BMC Pediatr. 2019 Sep 10;19(1):326. doi: 10.1186/s12887-019-1689-y.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PR(AMI)317/2012
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Medfödd hjärtsjukdom
-
Lifetech Scientific (Shenzhen) Co., Ltd.OkändPatent Ductus Arteriosus | Kanalberoende Cyanotic Congenital Heart DiseaseMalaysia
-
Region SkaneAnmälan via inbjudanHjärtsvikt New York Heart Association (NYHA) klass II | Hjärtsvikt New York Heart Association (NYHA) klass IIISverige
-
Taichung Veterans General HospitalRekryteringKontinuerlig Fetal Heart Beat Monitor och analys efter Spinal AnestesiTaiwan
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... och andra samarbetspartnersHar inte rekryterat ännuHjärtsvikt, systolisk | Hjärtsvikt Med Minskad Ejection Fraktion | Hjärtsvikt New York Heart Association Klass IV | Hjärtsvikt New York Heart Association Klass IIIPolen
-
University of WashingtonAmerican Heart AssociationAvslutadHjärtsvikt, Kongestiv | Mitokondriell förändring | Hjärtsvikt New York Heart Association Klass IVFörenta staterna
-
Novartis PharmaceuticalsAvslutadPatienter som framgångsrikt slutfört den 12 månader långa behandlingsperioden i kärnstudien (de Novo Heart Recipients) som var intresserade av att bli behandlad med EC-MPS
-
University Hospital, GasthuisbergOkändTransient Left Ventricular Ballooning SyndromeBelgien
-
Children's Hospital Medical Center, CincinnatiRekryteringNationellt samarbete för att förbättra vården av barn med komplexa medfödda hjärtsjukdomar (NPC-QIC)Hypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna, Storbritannien, Kanada
-
Mayo ClinicRekryteringHypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna
-
NYU Langone HealthRekryteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeFörenta staterna
Kliniska prövningar på Sonography
-
Yonsei UniversityOkändAllmän anestesiKorea, Republiken av
-
Sohag UniversityHar inte rekryterat ännu